NOI - Whole Genome Sequencing-Sickle Cell Patient

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.
(ii) The solicitation number is (insert solicitation number) and the solicitation is issued as a Notice of Intent (NOI) of a non-competitive (notice of intent) combined synopsis solicitation to award a contract or purchase order without providing for full or open competition (including brand-name).
This acquisition is conducted under the authority of the FAR Part 12.603 Streamlined solicitation for commercial products or commercial services and is not expected to exceed the simplified acquisition threshold, and the authority of 41 U.S.C. 1901 and the statutory authority of FAR 6.302-3(a)(2)(ii).
The National Institutes of Health, Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order without providing for full and open competition (Including brand-name) to The Broad Institute, Inc. 415 Main Street Cambridge, MA 02142 for whole genome sequencing services.
The purpose of this acquisition is to obtain high-quality whole genome sequencing (WGS) services for sickle cell disease (SCD) patient samples to support ongoing genomic research and predictive modeling efforts. The Broad Institute is uniquely positioned to perform this requirement due to its prior sequencing of this specific cohort and use of established sequencing and bioinformatics pipelines aligned with existing datasets. Use of another vendor would introduce data variability, require reprocessing or validation of prior datasets, and pose unacceptable technical and programmatic risk.